Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Hudis

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Seminars in Oncology|September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancerJ Baselga, D Tripathy, J Mendelsohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancerC A Hudis, A D Seidman, J P Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancerA D Seidman, D Hochhauser, M Gollub, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2001
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trialT Gilewski, G Ragupathi, S Bhuta, et al.
Breast Cancer Research and Treatment|June 17, 2016
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II studyL M Smyth, N M Iyengar, M F Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationA D Seidman, M N Fornier, F J Esteva, et al.
The Pharmacogenomics Journal|February 12, 2014
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance)A Chhibber, J Mefford, E A Stahl, et al.
Prostate Cancer and Prostatic Diseases|June 28, 2017
Periprostatic adipose inflammation is associated with high-grade prostate cancerA Gucalp, N M Iyengar, X K Zhou, et al.
Breast Cancer Research and Treatment|November 21, 2016
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)Rachel A Freedman, D K Seisler, J C Foster, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Seminars in Oncology|September 11, 1999
Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancerJ Baselga, D Tripathy, J Mendelsohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2016
Research needs in breast cancerF Cardoso, N Harbeck, C H Barrios, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancerC A Hudis, A D Seidman, J P Crown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancerA D Seidman, D Hochhauser, M Gollub, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 15, 2001
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trialT Gilewski, G Ragupathi, S Bhuta, et al.
Breast Cancer Research and Treatment|June 17, 2016
Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II studyL M Smyth, N M Iyengar, M F Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationA D Seidman, M N Fornier, F J Esteva, et al.
The Pharmacogenomics Journal|February 12, 2014
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance)A Chhibber, J Mefford, E A Stahl, et al.
Prostate Cancer and Prostatic Diseases|June 28, 2017
Periprostatic adipose inflammation is associated with high-grade prostate cancerA Gucalp, N M Iyengar, X K Zhou, et al.
Breast Cancer Research and Treatment|November 21, 2016
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511)Rachel A Freedman, D K Seisler, J C Foster, et al.
Pageof 5